Johnson & Johnson

JNJ is one of those companies that needs no introduction. The conglomerate has built a healthcare empire by developing, manufacturing, and marketing a wide range of healthcare products. They might be best known for Tylenol and baby powder, but this company’s reach also extends behind-the-counter including medical devices such as surgical instruments and joint replacements.

$161.72
(as of Mar 26, 7:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Johnson & Johnson

Stock Price
$161.72
Ticker Symbol
JNJ
Exchange
NYSE

Industry Information for Johnson & Johnson

Sector
Healthcare
Industry
Drug Manufacturers - General

Company Description for Johnson & Johnson

Country
USA
Full Time Employees
138,100

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Fundamentals for Johnson & Johnson

Market Capitalization
$388,034,068,480
EBITDA
$29,940,000,768
Dividends per Share
$4.91
P/E Ratio
27.76
Forward P/E Ratio
15.2
Earnings per Share
$5.80
Earnings per Share Estimate Next Year
Profit Margin
15.84%
Shares Outstanding
2,409,850,112
Percent Owned by Insiders
0.06%
Percent Owned by Institutions
73.56%
52-Week High
52-Week Low

Technical Indicators for Johnson & Johnson

50-Day Moving Average
200-Day Moving Average
RSI
50.14
2.47

Analyst Ratings for Johnson & Johnson

Strong Buy
7
Buy
3
Hold
13
Sell
0
Strong Sell
0

News About Johnson & Johnson

Mar 26, 2025, 12:37 PM EST
Johnson & Johnson (JNJ) said Wednesday that results from a phase 3 trial showed that Rybrevant as a See more.
Mar 26, 2025, 11:45 AM EST
Median overall survival not yet reached with projected improvement of more than one year versus osimertinib See more.
Mar 26, 2025, 9:40 AM EST
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. See more.
Mar 26, 2025, 9:00 AM EST
Earnings are arguably the most important single number on a company's quarterly financial report. See more.